Re³ (Re-Cube: Retain Remicade® Response)(Study P04249AM3)

PHASE3TerminatedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

March 31, 2006

Primary Completion Date

October 31, 2008

Study Completion Date

October 31, 2008

Conditions
Rheumatoid Arthritis
Interventions
DRUG

Infliximab Increased Frequency

Continuing the same dose of 3 mg/kg infliximab, but at every 6 weeks for 24 weeks

DRUG

Infliximab Increased Dose

3 mg/kg infliximab + 1 extra vial (100 mg) infliximab every 8 weeks for 24 weeks

DRUG

Infliximab Control

Continuation of infliximab 3 mg/kg every 8 weeks for 24 weeks

Sponsors
All Listed Sponsors
collaborator

Integrated Therapeutics Group

INDUSTRY

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00394589 - Re³ (Re-Cube: Retain Remicade® Response)(Study P04249AM3) | Biotech Hunter | Biotech Hunter